Effectiveness of treatment with direct-acting antiviral drugs in patients with hepatitis C treated at a referral center in the Pará Sate, Brazil, from 2017 to 2019/Efetividade do tratamento com drogas antivirais de ação direta em pacientes com hepatite C atendidos em um centro de referência no estado do Pará, Brasil, de 2017 a 2019

Borges Neto, Francisco das Chagas; Souza, Madson Guilherme Lobato de; Novaes, Inah Camila do Rosário Barata; Silveira, Vinicius Sousa da; Nunes, Mayara Pantoja; Miranda, Gabriel Castelo Branco Melo; Moia, Lizomar de Jesus Maués Pereira; Barbosa, Maria Silvia de Brito; Miranda, Esther Castello Branco Mello.
Rev. Pan-Amaz. Saude ; 11: e202000468, 2020.
Artigo em Português | Instituto Evandro Chagas (SOPHIA) | ID: iec-20810

Documentos relacionados

  1. Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line.
  2. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.
  3. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.
  4. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
  5. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
  6. Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.
  7. Treatment of chronic hepatitis C with direct-acting antivirals in patients with ß-thalassaemia major and advanced liver disease.
  8. Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
  9. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
  10. Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.